PROK stock icon

ProKidney
PROK

$2.23
1.3%
 

About: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.

Employees: 163

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 4 analysts
0
News positive %
of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

3.75% less ownership

Funds ownership: 43.76% [Q4 2023] → 40.01% (-3.75%) [Q1 2024]

10% less funds holding

Funds holding: 61 [Q4 2023] → 55 (-6) [Q1 2024]

16% less capital invested

Capital invested by funds: $52.3M [Q4 2023] → $44.1M (-$8.16M) [Q1 2024]

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

50% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 24

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $10K

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$2
10%
downside
Avg. target
$3.75
68%
upside
High target
$6
169%
upside

4 analyst ratings

positive
25%
neutral
75%
negative
0%
Jefferies
Kelly Shi
169%upside
$6
Buy
Maintained
10 Jun 2024
B of A Securities
Jason Gerberry
79%upside
$4
Neutral
Maintained
29 May 2024
Morgan Stanley
Judah Frommer
35%upside
$3
Equal-Weight
Assumed
7 Mar 2024
B of A Securities
Jason Gerberry
10%downside
$2
Neutral
Downgraded
2 Jan 2024

Financial journalist opinion

Based on 5 articles about PROK published over the past 30 days